LIPIDOMICS SHARED RESOURCE GROUP

脂质组学共享资源的使命是提供先进的方法学、最先进的 该公司拥有先进的设备和专业知识，以具有成本效益的方式为Hollings癌症中心（HCC）合成和分析生物活性脂质。这种共享资源还促进了HCC内的研究人员、其他共享设施和项目之间的互动，以及与国内和国际上的其他癌症研究小组的互动。在董事Besim Ogretmen博士和运营总监Alicja Bielawska的领导下，Lipidomics共享资源代表了一种独特的科学服务，用于测量生物活性脂质分子，特别关注其在癌症中的作用。 Lipidomics共享资源的目的是： * 提供合成脂质，类似物和脂质代谢抑制剂，重点是鞘脂。 * 提供生物材料脂质成分的定性和定量分析， 列出了300多种不同的分子物种。 * 通过提供脂质数据库，改进和开发扩展脂质分析的新技术 正常和转化的细胞和细胞器的组成，这将允许脂质组学方法， 分析他们的细胞代谢。 * 开发尖端的合成分子工具，研究生物活性脂质作为新潜力的作用 抗癌剂。 * 开发用于转化研究的先导化合物。Lipidomics共享资源的合成脂质，衍生物和相关分子库目前超过600种化合物，其中一些正在成为鞘脂代谢酶的重要抑制剂，并正在临床试验中进行测试。 * 教育和协助HCC研究人员设计和实施实验方法， 对生物活性脂质、其代谢、定量和功能的研究。 在目前的CCSG项目期间，Lipidomics共享资源支持了17名HCC研究人员的103篇出版物。它在项目期间支持了MUSC的19项个人癌症赠款，以及NIH脂质组学和病理学卓越生物医学研究中心（COBRE）（P20 RR 017677，2002-2012; P30 GM 103339，2012-2017）。

The mission of the Lipidomics Shared Resource is to provide advanced methodology, state-of-the-art facilities, and expertise for both synthesis and analysis of bioactive lipids in a cost-effective manner for the Hollings Cancer Center (HCC). This shared resource also facilitates interactions among investigators, other shared facilities, and programs within the HCC as well as with other cancer research groups nationally and internationally. Under the leadership of Drs. Besim Ogretmen, Director, and Alicja Bielawska, Operations Director, the Lipidomics Shared Resource represents a unique scientific service for the measurement of bioactive lipid molecules with a particular focus on their role in cancers. The purposes of the Lipidomics Shared Resource are to: * Provide synthetic lipids, analogs, and inhibitors of lipid metabolism with an emphasis on sphingolipids. * Provide qualitative and quantitative analysis of lipid composition from biological materials with a current listing of more than 300 distinct molecular species. * Improve and develop new techniques for extended lipid analyses by providing a database of the lipid composition of normal and transformed cells and organelles that will permit a lipidomics approach to analysis of their cellular metabolism. * Develop cutting-edge synthetic molecular tools to study the role of bioactive lipids as new potential anticancer agents. * Develop lead compounds for translational studies. The Lipidomics Shared Resource's library of synthetic lipids, derivatives, and related molecules currently exceeds 600 compounds, several of which are emerging as Important inhibitors of enzymes of sphingolipid metabolism and being tested in clinical trials. * Educate and assist HCC investigators in designing and conducting experimental approaches aimed at the study of bioactive lipids, their metabolism, quantitation, and function. During the current CCSG project period, the Lipidomics Shared Resource has supported research that has resulted in 103 publications by 17 HCC investigators. It has supported 19 individual cancer grants at MUSC during the project period and an NIH Center of Biomedical Research Excellence (COBRE) in Lipidomics & Pathobiology (P20 RR017677, 2002-2012; P30 GM103339, 2012-2017).